* Acutus Medical Inc AFIB.OQ AFIB.O is expected to show
a fall
in quarterly revenue when it reports results on November 10.
* The Carlsbad California-based company is expected to
report a
20.7% decrease in revenue to $3.65 million from $4.6 million a
year ago, according to the mean estimate from 6 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Acutus Medical Inc
is for
a loss of 81 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Acutus
Medical
Inc is $2, above its last closing price of $0.91.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.82 -0.80 -1.38 Missed -73.4
Mar. 31 2022 -0.94 -0.92 -1.00 Missed -8.3
Dec. 31 2021 -0.95 -0.83 -1.12 Missed -34.1
Sep. 30 2021 -0.85 -0.87 -0.94 Missed -8.5
Jun. -0.92 -0.84 -1.02 Missed -21.7
30 2021
Mar. 31 2021 -0.85 -0.81 -1.04 Missed -28.1
Dec. 31 2020 -0.74 -0.72 -1.05 Missed -45.4
Sep. 30 2020 -1.06 -0.99 -1.95 Missed -96.6
This summary was machine generated November 9 at 03:05 GMT. All
figures in US dollars unless otherwise stated